このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

2014年1月31日 更新者:Richard Burt, MD

Umbilical Cord Blood Stem Cell Injection for Critical Limb Ischemia

The purpose of this study is to determine whether treatment with umbilical cord blood stem cells will improve blood flow to the most severely affected leg of a participant with medically refractory and non-surgical peripheral vascular disease of the lower extremity.

調査の概要

状態

終了しました

詳細な説明

Umbilical cord blood is a safe alternative source of stem cells used for decades in hematopoietic stem cell transplants for malignancies. There is also a reported decreased incidence of acute GVHD compared to matched unrelated donor transplants.A cord blood registry will be searched for suitable units with compatibility in the ABO and HLA systems. The minimum total nucleated cell dose required which would be 1.0 x 107/kg, and one unit of cells will be procured to meet this requirement. Although it is likely that the transplanted cord blood cells will be rejected over time, we hypothesize that while they remain in the host's tissue these cells will be producing and releasing cytokines, growth factors and other humoral factors that might promote vasculogenesis by stimulating endogenous stem cells and endothelial cells. Since there is no need to collect the patient's own stem cells, the patient's cardiovascular system will not be subjected to any stress due to the leukapheresis procedure itself. No injections of exogenous growth factors, which have been associated with thrombosis, would be required to mobilize the patient's own stem cells. The procedure could conceivably even be performed in its entirety on an outpatient basis.

A total of 25 patients will be enrolled in the study. Patients will be followed for 24 months after the procedure with evaluation visits one day after the transplant and then at one month, six, twelve and twenty four months post-treatment. The visit one day after the transplant will involve a history and physical with a leg exam, a CBC and a chemistry panel to evaluate for possible infection, or other adverse event.

研究の種類

介入

入学 (実際)

1

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • Northwestern University

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~72年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Atherosclerotic ischemic peripheral vascular disease or Thromboangiitis Obliterans with Critical Limb Ischemia (Fontaine stages III and IV)
  • Participant must match either a or b

    1. Ankle brachial index (ABI) ≤ 0.7
    2. Doppler waveforms at posterior tibial artery and dorsalis pedis artery are monophasic with toe pressure < 30 mmHg.
  • A non-surgical candidate for revascularization e.g. prior vascular reconstruction, inability to locate a suitable vein for grafting, diffuse multi- segment disease, or extensive infra-popliteal disease not amenable to a vascular graft.
  • Age > 18 years old.
  • The non-index leg may be treated only in the event and it full fills the same eligibility criteria and exclusion criteria used in this protocol for the treatment leg.
  • Patients must be on maximal tolerated medical therapy for PVD including A) Cessation of smoking B) Referral to endocrinologist for control of HgA1c to < 7.0 mg/dl, control of hyperlipidemia with statins or other anti-hyperlipidemic drugs as indicated, control of hypertension as indicated C) Antiplatelet therapy with aspirin and / or cilostazol (unless medically contraindicated, e.g. bleeding or allergy)

Exclusion Criteria:

  • Popliteal vascular entrapment syndrome
  • Lower extremity infection or infected ulcer
  • Hypercoagulable state
  • HIV positive
  • HBsAg positive
  • Uncontrolled arrhythmia, that is, persistence of an arrhythmia despite medical therapy
  • Unstable angina
  • Thrombocytopenia < 50,000/ul
  • Leukemia or myelodysplasia
  • Allergy to E coli or its products
  • Patients with metal in their bodies cannot undergo MRIs (MRA). Therefore, patients with, cochlear implants, or aneurysm clips are not eligible. Coronary artery stents are not a contraindication. Patients with pacemakers are still candidates provided they have normal creatinine (< 1.1 mg/dl) and can receive contrast dye (no allergy) for angiogram instead of MRA. MRI/MRA does not need to be repeated if a prior MRA or Angiogram Demonstrates inoperable disease.
  • Patients who are pregnant
  • Poorly controlled diabetes will not be a cause for exclusion but patient must see endocrinologist for better control
  • Current malignancy, except squamous cell or basal cell skin cancers thought to be easily controlled.
  • AST, ALT, or bilirubin more than twice the upper limit of normal.
  • WBC < 2.5 / ul.
  • Any patient who is actively bleeding, including blood on urine dipstick or fecal occult blood.
  • Patient is on chemotherapy or other immuno-suppressive medications such as steroids, cellcept, cyclosporine, cytoxan, azathioprine, rituxan, humira or remicade.
  • Donor is HLA homozygous and shares that HLA haplotype with the recipient (a different donor will have to be found)
  • Patients diagnosed with Thromboangiitis Obliterans (Buerger's Disease) who are smokers and are unwilling or unable to quit smoking
  • A) Patients with a myocardial infarction within the last 30 days or left ventricular ejection fraction < 35% B) Patients with a history of malignancy in the last 5 years (other than basal cell carcinoma or carcinoma in situ) C) Patients with a CVA within the last 6 months D) Patients with a HbA1c level > 7.0%

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:UBC injection into one leg of PVD pt
25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.

The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.

Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois).

他の名前:
  • HSCT

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
Ankle brachial index (ABI), a 15% increase will be considered improvement
時間枠:Pre-transplant, 1, 6, 12 and 24 months after
Pre-transplant, 1, 6, 12 and 24 months after
Healing of ischemic ulcers
時間枠:Pre-transplant, 1, 6, 12 and 24 months after
Pre-transplant, 1, 6, 12 and 24 months after
Decreased pain level as reported by the patient
時間枠:Pre-transplant, 1, 6, 12 and 24 months after
Pre-transplant, 1, 6, 12 and 24 months after

二次結果の測定

結果測定
時間枠
SF-36 quality of life (QOL)
時間枠:Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Walking Impairment Questionnaire
時間枠:Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Increase in pain free ambulation time on treadmill by more than 25%
時間枠:Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Increase in four meter walk or six minute walk by more than 25%
時間枠:Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Richard Burt, MD、Northwestern University and Northwestern Memorial Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2009年11月1日

一次修了 (実際)

2014年1月1日

研究の完了 (実際)

2014年1月1日

試験登録日

最初に提出

2009年11月19日

QC基準を満たした最初の提出物

2009年11月24日

最初の投稿 (見積もり)

2009年11月25日

学習記録の更新

投稿された最後の更新 (見積もり)

2014年2月3日

QC基準を満たした最後の更新が送信されました

2014年1月31日

最終確認日

2014年1月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • PVD.Cord.Blood.2008

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する